Journal
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
Volume 4, Issue 7, Pages 909-922Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/17425255.4.7.909
Keywords
CYP3A4; drug-drug interactions; intestinal first-pass
Ask authors/readers for more resources
Background: The contribution of intestine to the magnitude of drug-drug interactions (DDI) may be significant, considering high levels of inhibitors in the gut lumen achieved during absorption and the abundance of metabolic enzymes in the mature enterocytes. Intestinal inhibition is incorporated in the DDI prediction models as the ratio of the intestinal wall availability in the presence and absence of the inhibitor (F-G' and F-G, respectively). Objective: This review will focus on the ability of the current approaches to estimate the extent of intestinal DDI accurately, addressing predominantly the most abundant intestinal P450 enzyme, CYP3A4. Methods: Considering the sensitivity of the DDI prediction models to the accuracy of the FG estimates, the current study focuses on 3 different in vitro and in vivo approaches to assess this parameter. Results/conclusion: The advantages and limitations of each of FG methods are outlined. Accurate assessment of this parameter is essential for the prediction of human drug clearance and drug-drug interaction potential.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available